nodes	percent_of_prediction	percent_of_DWPC	metapath
Orlistat—CYP3A4—Everolimus—kidney cancer	0.0663	0.293	CbGbCtD
Orlistat—CYP3A4—Temsirolimus—kidney cancer	0.0448	0.198	CbGbCtD
Orlistat—CYP3A4—Pazopanib—kidney cancer	0.0235	0.104	CbGbCtD
Orlistat—CYP3A4—Erlotinib—kidney cancer	0.0168	0.0741	CbGbCtD
Orlistat—CYP3A4—Paclitaxel—kidney cancer	0.0154	0.0679	CbGbCtD
Orlistat—CYP3A4—Sorafenib—kidney cancer	0.0137	0.0603	CbGbCtD
Orlistat—CYP3A4—Vinblastine—kidney cancer	0.0135	0.0595	CbGbCtD
Orlistat—CYP3A4—Vincristine—kidney cancer	0.0133	0.0585	CbGbCtD
Orlistat—CYP3A4—Sunitinib—kidney cancer	0.0111	0.0488	CbGbCtD
Orlistat—CYP3A4—Doxorubicin—kidney cancer	0.00828	0.0366	CbGbCtD
Orlistat—DAGLB—kidney—kidney cancer	0.00561	0.235	CbGeAlD
Orlistat—FASN—Sirolimus—Temsirolimus—kidney cancer	0.00453	0.441	CbGdCrCtD
Orlistat—FASN—Sirolimus—Everolimus—kidney cancer	0.00453	0.441	CbGdCrCtD
Orlistat—ABHD16A—cortex of kidney—kidney cancer	0.00414	0.174	CbGeAlD
Orlistat—ABHD12—cortex of kidney—kidney cancer	0.00388	0.163	CbGeAlD
Orlistat—ABHD12—cardiac atrium—kidney cancer	0.00369	0.155	CbGeAlD
Orlistat—CYP3A4—urine—kidney cancer	0.00224	0.0939	CbGeAlD
Orlistat—PLA2G4A—renal system—kidney cancer	0.00166	0.0697	CbGeAlD
Orlistat—PLA2G4A—cortex of kidney—kidney cancer	0.00157	0.0656	CbGeAlD
Orlistat—FASN—Azacitidine—Gemcitabine—kidney cancer	0.00122	0.119	CbGdCrCtD
Orlistat—CYP3A4—renal system—kidney cancer	0.000549	0.023	CbGeAlD
Orlistat—CYP3A4—kidney—kidney cancer	0.00053	0.0222	CbGeAlD
Orlistat—Urinary tract disorder—Capecitabine—kidney cancer	0.000285	0.000615	CcSEcCtD
Orlistat—Menopausal symptoms—Doxorubicin—kidney cancer	0.000285	0.000615	CcSEcCtD
Orlistat—Hypersensitivity—Sorafenib—kidney cancer	0.000284	0.000615	CcSEcCtD
Orlistat—Insomnia—Vincristine—kidney cancer	0.000284	0.000614	CcSEcCtD
Orlistat—Oedema peripheral—Capecitabine—kidney cancer	0.000284	0.000614	CcSEcCtD
Orlistat—Vomiting—Vinblastine—kidney cancer	0.000284	0.000614	CcSEcCtD
Orlistat—Dizziness—Erlotinib—kidney cancer	0.000284	0.000613	CcSEcCtD
Orlistat—Ill-defined disorder—Paclitaxel—kidney cancer	0.000284	0.000613	CcSEcCtD
Orlistat—Vomiting—Everolimus—kidney cancer	0.000283	0.000611	CcSEcCtD
Orlistat—Urethral disorder—Capecitabine—kidney cancer	0.000282	0.000611	CcSEcCtD
Orlistat—Paraesthesia—Vincristine—kidney cancer	0.000282	0.00061	CcSEcCtD
Orlistat—Dermatitis bullous—Doxorubicin—kidney cancer	0.000281	0.000607	CcSEcCtD
Orlistat—Rash—Everolimus—kidney cancer	0.00028	0.000606	CcSEcCtD
Orlistat—Dermatitis—Everolimus—kidney cancer	0.00028	0.000606	CcSEcCtD
Orlistat—Headache—Vinblastine—kidney cancer	0.00028	0.000605	CcSEcCtD
Orlistat—Angioedema—Paclitaxel—kidney cancer	0.000279	0.000604	CcSEcCtD
Orlistat—Headache—Everolimus—kidney cancer	0.000278	0.000602	CcSEcCtD
Orlistat—Abdominal pain—Dactinomycin—kidney cancer	0.000278	0.000601	CcSEcCtD
Orlistat—Body temperature increased—Dactinomycin—kidney cancer	0.000278	0.000601	CcSEcCtD
Orlistat—Asthenia—Sorafenib—kidney cancer	0.000277	0.000599	CcSEcCtD
Orlistat—Malaise—Paclitaxel—kidney cancer	0.000276	0.000596	CcSEcCtD
Orlistat—Hypoglycaemia—Doxorubicin—kidney cancer	0.000275	0.000595	CcSEcCtD
Orlistat—Vertigo—Paclitaxel—kidney cancer	0.000275	0.000594	CcSEcCtD
Orlistat—Hypersensitivity—Sunitinib—kidney cancer	0.000274	0.000592	CcSEcCtD
Orlistat—Decreased appetite—Vincristine—kidney cancer	0.000273	0.00059	CcSEcCtD
Orlistat—Pruritus—Sorafenib—kidney cancer	0.000273	0.00059	CcSEcCtD
Orlistat—Vomiting—Erlotinib—kidney cancer	0.000273	0.00059	CcSEcCtD
Orlistat—Musculoskeletal discomfort—Gemcitabine—kidney cancer	0.000271	0.000587	CcSEcCtD
Orlistat—Gastrointestinal disorder—Vincristine—kidney cancer	0.000271	0.000586	CcSEcCtD
Orlistat—Fatigue—Vincristine—kidney cancer	0.000271	0.000586	CcSEcCtD
Orlistat—Rash—Erlotinib—kidney cancer	0.00027	0.000585	CcSEcCtD
Orlistat—Dermatitis—Erlotinib—kidney cancer	0.00027	0.000584	CcSEcCtD
Orlistat—Palpitations—Paclitaxel—kidney cancer	0.00027	0.000584	CcSEcCtD
Orlistat—Insomnia—Gemcitabine—kidney cancer	0.000269	0.000583	CcSEcCtD
Orlistat—Headache—Erlotinib—kidney cancer	0.000269	0.000581	CcSEcCtD
Orlistat—Pain—Vincristine—kidney cancer	0.000269	0.000581	CcSEcCtD
Orlistat—Osteoarthritis—Doxorubicin—kidney cancer	0.000268	0.000581	CcSEcCtD
Orlistat—Paraesthesia—Gemcitabine—kidney cancer	0.000268	0.000579	CcSEcCtD
Orlistat—Cough—Paclitaxel—kidney cancer	0.000267	0.000577	CcSEcCtD
Orlistat—Asthenia—Sunitinib—kidney cancer	0.000266	0.000576	CcSEcCtD
Orlistat—Nausea—Vinblastine—kidney cancer	0.000265	0.000573	CcSEcCtD
Orlistat—Convulsion—Paclitaxel—kidney cancer	0.000265	0.000573	CcSEcCtD
Orlistat—Nausea—Everolimus—kidney cancer	0.000264	0.000571	CcSEcCtD
Orlistat—Diarrhoea—Sorafenib—kidney cancer	0.000264	0.000571	CcSEcCtD
Orlistat—Pruritus—Sunitinib—kidney cancer	0.000263	0.000568	CcSEcCtD
Orlistat—Immune system disorder—Capecitabine—kidney cancer	0.00026	0.000563	CcSEcCtD
Orlistat—Myalgia—Paclitaxel—kidney cancer	0.00026	0.000563	CcSEcCtD
Orlistat—Chest pain—Paclitaxel—kidney cancer	0.00026	0.000563	CcSEcCtD
Orlistat—Mediastinal disorder—Capecitabine—kidney cancer	0.00026	0.000562	CcSEcCtD
Orlistat—Anxiety—Paclitaxel—kidney cancer	0.000259	0.000561	CcSEcCtD
Orlistat—Decreased appetite—Gemcitabine—kidney cancer	0.000259	0.00056	CcSEcCtD
Orlistat—Hypersensitivity—Dactinomycin—kidney cancer	0.000259	0.00056	CcSEcCtD
Orlistat—Unspecified disorder of skin and subcutaneous tissue—Paclitaxel—kidney cancer	0.000258	0.000559	CcSEcCtD
Orlistat—Gastrointestinal disorder—Gemcitabine—kidney cancer	0.000257	0.000556	CcSEcCtD
Orlistat—Discomfort—Paclitaxel—kidney cancer	0.000257	0.000556	CcSEcCtD
Orlistat—Fatigue—Gemcitabine—kidney cancer	0.000257	0.000555	CcSEcCtD
Orlistat—Gastrointestinal pain—Vincristine—kidney cancer	0.000257	0.000555	CcSEcCtD
Orlistat—Dizziness—Sorafenib—kidney cancer	0.000255	0.000552	CcSEcCtD
Orlistat—Pain—Gemcitabine—kidney cancer	0.000255	0.000551	CcSEcCtD
Orlistat—Nausea—Erlotinib—kidney cancer	0.000255	0.000551	CcSEcCtD
Orlistat—Alopecia—Capecitabine—kidney cancer	0.000255	0.000551	CcSEcCtD
Orlistat—Dry mouth—Paclitaxel—kidney cancer	0.000254	0.00055	CcSEcCtD
Orlistat—Diarrhoea—Sunitinib—kidney cancer	0.000254	0.000549	CcSEcCtD
Orlistat—Mental disorder—Capecitabine—kidney cancer	0.000252	0.000546	CcSEcCtD
Orlistat—Asthenia—Dactinomycin—kidney cancer	0.000252	0.000545	CcSEcCtD
Orlistat—Malnutrition—Capecitabine—kidney cancer	0.000251	0.000542	CcSEcCtD
Orlistat—Anaphylactic shock—Paclitaxel—kidney cancer	0.000249	0.000539	CcSEcCtD
Orlistat—Oedema—Paclitaxel—kidney cancer	0.000249	0.000539	CcSEcCtD
Orlistat—Body temperature increased—Vincristine—kidney cancer	0.000248	0.000537	CcSEcCtD
Orlistat—Abdominal pain—Vincristine—kidney cancer	0.000248	0.000537	CcSEcCtD
Orlistat—Infection—Paclitaxel—kidney cancer	0.000248	0.000536	CcSEcCtD
Orlistat—Flatulence—Capecitabine—kidney cancer	0.000247	0.000534	CcSEcCtD
Orlistat—Dry skin—Doxorubicin—kidney cancer	0.000246	0.000532	CcSEcCtD
Orlistat—Dysgeusia—Capecitabine—kidney cancer	0.000246	0.000531	CcSEcCtD
Orlistat—Dizziness—Sunitinib—kidney cancer	0.000246	0.000531	CcSEcCtD
Orlistat—Feeling abnormal—Gemcitabine—kidney cancer	0.000246	0.000531	CcSEcCtD
Orlistat—Vomiting—Sorafenib—kidney cancer	0.000245	0.000531	CcSEcCtD
Orlistat—Abdominal pain upper—Doxorubicin—kidney cancer	0.000245	0.00053	CcSEcCtD
Orlistat—Nervous system disorder—Paclitaxel—kidney cancer	0.000245	0.000529	CcSEcCtD
Orlistat—Hypokalaemia—Doxorubicin—kidney cancer	0.000244	0.000528	CcSEcCtD
Orlistat—Rash—Sorafenib—kidney cancer	0.000243	0.000526	CcSEcCtD
Orlistat—Dermatitis—Sorafenib—kidney cancer	0.000243	0.000526	CcSEcCtD
Orlistat—Back pain—Capecitabine—kidney cancer	0.000243	0.000525	CcSEcCtD
Orlistat—Breast disorder—Doxorubicin—kidney cancer	0.000243	0.000525	CcSEcCtD
Orlistat—Skin disorder—Paclitaxel—kidney cancer	0.000242	0.000524	CcSEcCtD
Orlistat—Headache—Sorafenib—kidney cancer	0.000242	0.000523	CcSEcCtD
Orlistat—Muscle spasms—Capecitabine—kidney cancer	0.000241	0.000521	CcSEcCtD
Orlistat—Hyperhidrosis—Paclitaxel—kidney cancer	0.000241	0.000521	CcSEcCtD
Orlistat—Diarrhoea—Dactinomycin—kidney cancer	0.000241	0.00052	CcSEcCtD
Orlistat—Gastritis—Doxorubicin—kidney cancer	0.000238	0.000514	CcSEcCtD
Orlistat—Vision blurred—Capecitabine—kidney cancer	0.000236	0.000511	CcSEcCtD
Orlistat—Vomiting—Sunitinib—kidney cancer	0.000236	0.000511	CcSEcCtD
Orlistat—Body temperature increased—Gemcitabine—kidney cancer	0.000236	0.000509	CcSEcCtD
Orlistat—Rash—Sunitinib—kidney cancer	0.000234	0.000506	CcSEcCtD
Orlistat—Dermatitis—Sunitinib—kidney cancer	0.000234	0.000506	CcSEcCtD
Orlistat—Abdominal distension—Doxorubicin—kidney cancer	0.000234	0.000505	CcSEcCtD
Orlistat—Ill-defined disorder—Capecitabine—kidney cancer	0.000233	0.000503	CcSEcCtD
Orlistat—Headache—Sunitinib—kidney cancer	0.000233	0.000503	CcSEcCtD
Orlistat—Influenza—Doxorubicin—kidney cancer	0.000232	0.000502	CcSEcCtD
Orlistat—Asthma—Doxorubicin—kidney cancer	0.000232	0.000502	CcSEcCtD
Orlistat—Hypersensitivity—Vincristine—kidney cancer	0.000231	0.0005	CcSEcCtD
Orlistat—Nausea—Sorafenib—kidney cancer	0.000229	0.000496	CcSEcCtD
Orlistat—Pancreatitis—Doxorubicin—kidney cancer	0.000228	0.000492	CcSEcCtD
Orlistat—Musculoskeletal discomfort—Paclitaxel—kidney cancer	0.000227	0.000491	CcSEcCtD
Orlistat—Malaise—Capecitabine—kidney cancer	0.000226	0.000489	CcSEcCtD
Orlistat—Insomnia—Paclitaxel—kidney cancer	0.000226	0.000488	CcSEcCtD
Orlistat—Vertigo—Capecitabine—kidney cancer	0.000225	0.000487	CcSEcCtD
Orlistat—Asthenia—Vincristine—kidney cancer	0.000225	0.000487	CcSEcCtD
Orlistat—Paraesthesia—Paclitaxel—kidney cancer	0.000224	0.000484	CcSEcCtD
Orlistat—Vomiting—Dactinomycin—kidney cancer	0.000223	0.000483	CcSEcCtD
Orlistat—Palpitations—Capecitabine—kidney cancer	0.000222	0.000479	CcSEcCtD
Orlistat—Rash—Dactinomycin—kidney cancer	0.000222	0.000479	CcSEcCtD
Orlistat—Nausea—Sunitinib—kidney cancer	0.000221	0.000477	CcSEcCtD
Orlistat—Dyspepsia—Paclitaxel—kidney cancer	0.00022	0.000475	CcSEcCtD
Orlistat—Cough—Capecitabine—kidney cancer	0.000219	0.000473	CcSEcCtD
Orlistat—Decreased appetite—Paclitaxel—kidney cancer	0.000217	0.000469	CcSEcCtD
Orlistat—Upper respiratory tract infection—Doxorubicin—kidney cancer	0.000216	0.000466	CcSEcCtD
Orlistat—Gastrointestinal disorder—Paclitaxel—kidney cancer	0.000215	0.000466	CcSEcCtD
Orlistat—Fatigue—Paclitaxel—kidney cancer	0.000215	0.000465	CcSEcCtD
Orlistat—Diarrhoea—Vincristine—kidney cancer	0.000215	0.000465	CcSEcCtD
Orlistat—Asthenia—Gemcitabine—kidney cancer	0.000214	0.000462	CcSEcCtD
Orlistat—Chest pain—Capecitabine—kidney cancer	0.000214	0.000462	CcSEcCtD
Orlistat—Myalgia—Capecitabine—kidney cancer	0.000214	0.000462	CcSEcCtD
Orlistat—Pain—Paclitaxel—kidney cancer	0.000213	0.000461	CcSEcCtD
Orlistat—Anxiety—Capecitabine—kidney cancer	0.000213	0.00046	CcSEcCtD
Orlistat—Unspecified disorder of skin and subcutaneous tissue—Capecitabine—kidney cancer	0.000212	0.000459	CcSEcCtD
Orlistat—Discomfort—Capecitabine—kidney cancer	0.000211	0.000456	CcSEcCtD
Orlistat—Pruritus—Gemcitabine—kidney cancer	0.000211	0.000456	CcSEcCtD
Orlistat—Dry mouth—Capecitabine—kidney cancer	0.000209	0.000452	CcSEcCtD
Orlistat—Nausea—Dactinomycin—kidney cancer	0.000209	0.000452	CcSEcCtD
Orlistat—Dizziness—Vincristine—kidney cancer	0.000208	0.000449	CcSEcCtD
Orlistat—Infestation—Doxorubicin—kidney cancer	0.000207	0.000447	CcSEcCtD
Orlistat—Infestation NOS—Doxorubicin—kidney cancer	0.000207	0.000447	CcSEcCtD
Orlistat—Feeling abnormal—Paclitaxel—kidney cancer	0.000206	0.000445	CcSEcCtD
Orlistat—Oedema—Capecitabine—kidney cancer	0.000205	0.000443	CcSEcCtD
Orlistat—Gastrointestinal pain—Paclitaxel—kidney cancer	0.000204	0.000441	CcSEcCtD
Orlistat—Diarrhoea—Gemcitabine—kidney cancer	0.000204	0.000441	CcSEcCtD
Orlistat—Renal failure—Doxorubicin—kidney cancer	0.000203	0.00044	CcSEcCtD
Orlistat—Infection—Capecitabine—kidney cancer	0.000203	0.00044	CcSEcCtD
Orlistat—Neuropathy peripheral—Doxorubicin—kidney cancer	0.000203	0.000439	CcSEcCtD
Orlistat—Urinary tract infection—Doxorubicin—kidney cancer	0.000201	0.000435	CcSEcCtD
Orlistat—Nervous system disorder—Capecitabine—kidney cancer	0.000201	0.000434	CcSEcCtD
Orlistat—Vomiting—Vincristine—kidney cancer	0.0002	0.000432	CcSEcCtD
Orlistat—Skin disorder—Capecitabine—kidney cancer	0.000199	0.00043	CcSEcCtD
Orlistat—Urticaria—Paclitaxel—kidney cancer	0.000198	0.000429	CcSEcCtD
Orlistat—Rash—Vincristine—kidney cancer	0.000198	0.000428	CcSEcCtD
Orlistat—Hyperhidrosis—Capecitabine—kidney cancer	0.000198	0.000428	CcSEcCtD
Orlistat—Dermatitis—Vincristine—kidney cancer	0.000198	0.000428	CcSEcCtD
Orlistat—Abdominal pain—Paclitaxel—kidney cancer	0.000197	0.000426	CcSEcCtD
Orlistat—Body temperature increased—Paclitaxel—kidney cancer	0.000197	0.000426	CcSEcCtD
Orlistat—Headache—Vincristine—kidney cancer	0.000197	0.000425	CcSEcCtD
Orlistat—Hepatobiliary disease—Doxorubicin—kidney cancer	0.000196	0.000423	CcSEcCtD
Orlistat—Sinusitis—Doxorubicin—kidney cancer	0.000194	0.00042	CcSEcCtD
Orlistat—Vomiting—Gemcitabine—kidney cancer	0.000189	0.00041	CcSEcCtD
Orlistat—Rash—Gemcitabine—kidney cancer	0.000188	0.000406	CcSEcCtD
Orlistat—Dermatitis—Gemcitabine—kidney cancer	0.000188	0.000406	CcSEcCtD
Orlistat—Haemoglobin—Doxorubicin—kidney cancer	0.000187	0.000404	CcSEcCtD
Orlistat—Headache—Gemcitabine—kidney cancer	0.000187	0.000404	CcSEcCtD
Orlistat—Nausea—Vincristine—kidney cancer	0.000187	0.000403	CcSEcCtD
Orlistat—Musculoskeletal discomfort—Capecitabine—kidney cancer	0.000187	0.000403	CcSEcCtD
Orlistat—Haemorrhage—Doxorubicin—kidney cancer	0.000186	0.000402	CcSEcCtD
Orlistat—Hepatitis—Doxorubicin—kidney cancer	0.000186	0.000402	CcSEcCtD
Orlistat—Insomnia—Capecitabine—kidney cancer	0.000185	0.0004	CcSEcCtD
Orlistat—Pharyngitis—Doxorubicin—kidney cancer	0.000184	0.000399	CcSEcCtD
Orlistat—Paraesthesia—Capecitabine—kidney cancer	0.000184	0.000397	CcSEcCtD
Orlistat—Hypersensitivity—Paclitaxel—kidney cancer	0.000184	0.000397	CcSEcCtD
Orlistat—Urinary tract disorder—Doxorubicin—kidney cancer	0.000183	0.000397	CcSEcCtD
Orlistat—Oedema peripheral—Doxorubicin—kidney cancer	0.000183	0.000396	CcSEcCtD
Orlistat—Urethral disorder—Doxorubicin—kidney cancer	0.000182	0.000394	CcSEcCtD
Orlistat—Dyspepsia—Capecitabine—kidney cancer	0.00018	0.00039	CcSEcCtD
Orlistat—Asthenia—Paclitaxel—kidney cancer	0.000179	0.000387	CcSEcCtD
Orlistat—Decreased appetite—Capecitabine—kidney cancer	0.000178	0.000385	CcSEcCtD
Orlistat—Nausea—Gemcitabine—kidney cancer	0.000177	0.000383	CcSEcCtD
Orlistat—Gastrointestinal disorder—Capecitabine—kidney cancer	0.000177	0.000382	CcSEcCtD
Orlistat—Fatigue—Capecitabine—kidney cancer	0.000176	0.000382	CcSEcCtD
Orlistat—Pruritus—Paclitaxel—kidney cancer	0.000176	0.000382	CcSEcCtD
Orlistat—Pain—Capecitabine—kidney cancer	0.000175	0.000379	CcSEcCtD
Orlistat—Diarrhoea—Paclitaxel—kidney cancer	0.000171	0.000369	CcSEcCtD
Orlistat—Feeling abnormal—Capecitabine—kidney cancer	0.000169	0.000365	CcSEcCtD
Orlistat—Immune system disorder—Doxorubicin—kidney cancer	0.000168	0.000363	CcSEcCtD
Orlistat—Gastrointestinal pain—Capecitabine—kidney cancer	0.000167	0.000362	CcSEcCtD
Orlistat—Mediastinal disorder—Doxorubicin—kidney cancer	0.000167	0.000362	CcSEcCtD
Orlistat—Dizziness—Paclitaxel—kidney cancer	0.000165	0.000357	CcSEcCtD
Orlistat—Alopecia—Doxorubicin—kidney cancer	0.000164	0.000355	CcSEcCtD
Orlistat—Mental disorder—Doxorubicin—kidney cancer	0.000163	0.000352	CcSEcCtD
Orlistat—Urticaria—Capecitabine—kidney cancer	0.000163	0.000352	CcSEcCtD
Orlistat—Abdominal pain—Capecitabine—kidney cancer	0.000162	0.00035	CcSEcCtD
Orlistat—Body temperature increased—Capecitabine—kidney cancer	0.000162	0.00035	CcSEcCtD
Orlistat—Malnutrition—Doxorubicin—kidney cancer	0.000162	0.00035	CcSEcCtD
Orlistat—Flatulence—Doxorubicin—kidney cancer	0.000159	0.000345	CcSEcCtD
Orlistat—Vomiting—Paclitaxel—kidney cancer	0.000159	0.000343	CcSEcCtD
Orlistat—Dysgeusia—Doxorubicin—kidney cancer	0.000158	0.000342	CcSEcCtD
Orlistat—Rash—Paclitaxel—kidney cancer	0.000157	0.00034	CcSEcCtD
Orlistat—Dermatitis—Paclitaxel—kidney cancer	0.000157	0.00034	CcSEcCtD
Orlistat—Back pain—Doxorubicin—kidney cancer	0.000156	0.000338	CcSEcCtD
Orlistat—Headache—Paclitaxel—kidney cancer	0.000156	0.000338	CcSEcCtD
Orlistat—Muscle spasms—Doxorubicin—kidney cancer	0.000155	0.000336	CcSEcCtD
Orlistat—Vision blurred—Doxorubicin—kidney cancer	0.000152	0.00033	CcSEcCtD
Orlistat—Hypersensitivity—Capecitabine—kidney cancer	0.000151	0.000326	CcSEcCtD
Orlistat—Ill-defined disorder—Doxorubicin—kidney cancer	0.00015	0.000324	CcSEcCtD
Orlistat—Nausea—Paclitaxel—kidney cancer	0.000148	0.00032	CcSEcCtD
Orlistat—Asthenia—Capecitabine—kidney cancer	0.000147	0.000318	CcSEcCtD
Orlistat—Malaise—Doxorubicin—kidney cancer	0.000146	0.000315	CcSEcCtD
Orlistat—Vertigo—Doxorubicin—kidney cancer	0.000145	0.000314	CcSEcCtD
Orlistat—Pruritus—Capecitabine—kidney cancer	0.000145	0.000313	CcSEcCtD
Orlistat—Palpitations—Doxorubicin—kidney cancer	0.000143	0.000309	CcSEcCtD
Orlistat—Cough—Doxorubicin—kidney cancer	0.000141	0.000305	CcSEcCtD
Orlistat—Convulsion—Doxorubicin—kidney cancer	0.00014	0.000303	CcSEcCtD
Orlistat—Diarrhoea—Capecitabine—kidney cancer	0.00014	0.000303	CcSEcCtD
Orlistat—Myalgia—Doxorubicin—kidney cancer	0.000138	0.000298	CcSEcCtD
Orlistat—Chest pain—Doxorubicin—kidney cancer	0.000138	0.000298	CcSEcCtD
Orlistat—Anxiety—Doxorubicin—kidney cancer	0.000137	0.000297	CcSEcCtD
Orlistat—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—kidney cancer	0.000137	0.000296	CcSEcCtD
Orlistat—Discomfort—Doxorubicin—kidney cancer	0.000136	0.000294	CcSEcCtD
Orlistat—Dizziness—Capecitabine—kidney cancer	0.000135	0.000293	CcSEcCtD
Orlistat—Dry mouth—Doxorubicin—kidney cancer	0.000135	0.000291	CcSEcCtD
Orlistat—Oedema—Doxorubicin—kidney cancer	0.000132	0.000285	CcSEcCtD
Orlistat—Anaphylactic shock—Doxorubicin—kidney cancer	0.000132	0.000285	CcSEcCtD
Orlistat—Infection—Doxorubicin—kidney cancer	0.000131	0.000283	CcSEcCtD
Orlistat—Vomiting—Capecitabine—kidney cancer	0.00013	0.000281	CcSEcCtD
Orlistat—Nervous system disorder—Doxorubicin—kidney cancer	0.000129	0.00028	CcSEcCtD
Orlistat—Rash—Capecitabine—kidney cancer	0.000129	0.000279	CcSEcCtD
Orlistat—Dermatitis—Capecitabine—kidney cancer	0.000129	0.000279	CcSEcCtD
Orlistat—Headache—Capecitabine—kidney cancer	0.000128	0.000277	CcSEcCtD
Orlistat—Skin disorder—Doxorubicin—kidney cancer	0.000128	0.000277	CcSEcCtD
Orlistat—Hyperhidrosis—Doxorubicin—kidney cancer	0.000128	0.000276	CcSEcCtD
Orlistat—Nausea—Capecitabine—kidney cancer	0.000122	0.000263	CcSEcCtD
Orlistat—Musculoskeletal discomfort—Doxorubicin—kidney cancer	0.00012	0.00026	CcSEcCtD
Orlistat—Insomnia—Doxorubicin—kidney cancer	0.000119	0.000258	CcSEcCtD
Orlistat—Paraesthesia—Doxorubicin—kidney cancer	0.000118	0.000256	CcSEcCtD
Orlistat—Dyspepsia—Doxorubicin—kidney cancer	0.000116	0.000251	CcSEcCtD
Orlistat—Decreased appetite—Doxorubicin—kidney cancer	0.000115	0.000248	CcSEcCtD
Orlistat—Gastrointestinal disorder—Doxorubicin—kidney cancer	0.000114	0.000246	CcSEcCtD
Orlistat—Fatigue—Doxorubicin—kidney cancer	0.000114	0.000246	CcSEcCtD
Orlistat—Pain—Doxorubicin—kidney cancer	0.000113	0.000244	CcSEcCtD
Orlistat—Feeling abnormal—Doxorubicin—kidney cancer	0.000109	0.000235	CcSEcCtD
Orlistat—Gastrointestinal pain—Doxorubicin—kidney cancer	0.000108	0.000233	CcSEcCtD
Orlistat—Urticaria—Doxorubicin—kidney cancer	0.000105	0.000227	CcSEcCtD
Orlistat—Abdominal pain—Doxorubicin—kidney cancer	0.000104	0.000226	CcSEcCtD
Orlistat—Body temperature increased—Doxorubicin—kidney cancer	0.000104	0.000226	CcSEcCtD
Orlistat—Hypersensitivity—Doxorubicin—kidney cancer	9.72e-05	0.00021	CcSEcCtD
Orlistat—Asthenia—Doxorubicin—kidney cancer	9.47e-05	0.000205	CcSEcCtD
Orlistat—Pruritus—Doxorubicin—kidney cancer	9.34e-05	0.000202	CcSEcCtD
Orlistat—Diarrhoea—Doxorubicin—kidney cancer	9.03e-05	0.000195	CcSEcCtD
Orlistat—Dizziness—Doxorubicin—kidney cancer	8.73e-05	0.000189	CcSEcCtD
Orlistat—Vomiting—Doxorubicin—kidney cancer	8.39e-05	0.000181	CcSEcCtD
Orlistat—Rash—Doxorubicin—kidney cancer	8.32e-05	0.00018	CcSEcCtD
Orlistat—Dermatitis—Doxorubicin—kidney cancer	8.31e-05	0.00018	CcSEcCtD
Orlistat—Headache—Doxorubicin—kidney cancer	8.27e-05	0.000179	CcSEcCtD
Orlistat—DAGLB—Signaling by GPCR—MAPK3—kidney cancer	8.02e-05	0.00029	CbGpPWpGaD
Orlistat—DAGLA—Signaling by GPCR—MAPK3—kidney cancer	8.02e-05	0.00029	CbGpPWpGaD
Orlistat—DAGLB—Signaling Pathways—POMC—kidney cancer	7.98e-05	0.000288	CbGpPWpGaD
Orlistat—DAGLA—Signaling Pathways—POMC—kidney cancer	7.98e-05	0.000288	CbGpPWpGaD
Orlistat—FASN—Disease—HIF1A—kidney cancer	7.96e-05	0.000288	CbGpPWpGaD
Orlistat—FASN—Disease—TSC2—kidney cancer	7.94e-05	0.000287	CbGpPWpGaD
Orlistat—FASN—Metabolism—GSTM1—kidney cancer	7.91e-05	0.000286	CbGpPWpGaD
Orlistat—PNLIP—Metabolism—POMC—kidney cancer	7.9e-05	0.000285	CbGpPWpGaD
Orlistat—PNLIP—Signaling Pathways—HIF1A—kidney cancer	7.88e-05	0.000285	CbGpPWpGaD
Orlistat—DAGLA—Signaling Pathways—BRAF—kidney cancer	7.88e-05	0.000284	CbGpPWpGaD
Orlistat—DAGLB—Signaling Pathways—BRAF—kidney cancer	7.88e-05	0.000284	CbGpPWpGaD
Orlistat—PNLIP—Signaling Pathways—TSC2—kidney cancer	7.86e-05	0.000284	CbGpPWpGaD
Orlistat—Nausea—Doxorubicin—kidney cancer	7.84e-05	0.000169	CcSEcCtD
Orlistat—PNLIP—Disease—RAF1—kidney cancer	7.78e-05	0.000281	CbGpPWpGaD
Orlistat—PNLIP—Disease—ERBB2—kidney cancer	7.7e-05	0.000278	CbGpPWpGaD
Orlistat—PLA2G4A—Integrated Pancreatic Cancer Pathway—MAPK3—kidney cancer	7.67e-05	0.000277	CbGpPWpGaD
Orlistat—DAGLB—Signaling by GPCR—MAPK1—kidney cancer	7.64e-05	0.000276	CbGpPWpGaD
Orlistat—DAGLA—Signaling by GPCR—MAPK1—kidney cancer	7.64e-05	0.000276	CbGpPWpGaD
Orlistat—CYP3A4—Cytochrome P450 - arranged by substrate type—POMC—kidney cancer	7.63e-05	0.000276	CbGpPWpGaD
Orlistat—PNLIP—Disease—MTOR—kidney cancer	7.6e-05	0.000274	CbGpPWpGaD
Orlistat—PNLIP—Disease—CD4—kidney cancer	7.58e-05	0.000274	CbGpPWpGaD
Orlistat—PNLIP—Signaling Pathways—KDR—kidney cancer	7.54e-05	0.000272	CbGpPWpGaD
Orlistat—PNLIP—Disease—PTGS2—kidney cancer	7.53e-05	0.000272	CbGpPWpGaD
Orlistat—FASN—Metabolism—CYP1A1—kidney cancer	7.5e-05	0.000271	CbGpPWpGaD
Orlistat—PLA2G4A—Integrated Pancreatic Cancer Pathway—MYC—kidney cancer	7.46e-05	0.000269	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism—CA9—kidney cancer	7.39e-05	0.000267	CbGpPWpGaD
Orlistat—CYP3A4—Biological oxidations—GSTT1—kidney cancer	7.3e-05	0.000264	CbGpPWpGaD
Orlistat—PLA2G4A—Integrated Pancreatic Cancer Pathway—MAPK1—kidney cancer	7.3e-05	0.000264	CbGpPWpGaD
Orlistat—DAGLA—GPCR downstream signaling—PIK3CA—kidney cancer	7.3e-05	0.000263	CbGpPWpGaD
Orlistat—DAGLB—GPCR downstream signaling—PIK3CA—kidney cancer	7.3e-05	0.000263	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism of lipids and lipoproteins—CYP1A1—kidney cancer	7.23e-05	0.000261	CbGpPWpGaD
Orlistat—PLA2G4A—Platelet activation, signaling and aggregation—VEGFA—kidney cancer	7.21e-05	0.000261	CbGpPWpGaD
Orlistat—DAGLB—Signaling by GPCR—KRAS—kidney cancer	7.21e-05	0.00026	CbGpPWpGaD
Orlistat—DAGLA—Signaling by GPCR—KRAS—kidney cancer	7.21e-05	0.00026	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—SFRP2—kidney cancer	7.13e-05	0.000258	CbGpPWpGaD
Orlistat—PNLIP—Disease—CDKN1B—kidney cancer	7.13e-05	0.000257	CbGpPWpGaD
Orlistat—FASN—Disease—APC—kidney cancer	7.01e-05	0.000253	CbGpPWpGaD
Orlistat—FASN—Disease—KIT—kidney cancer	7.01e-05	0.000253	CbGpPWpGaD
Orlistat—PNLIP—Signaling Pathways—KIT—kidney cancer	6.94e-05	0.000251	CbGpPWpGaD
Orlistat—PNLIP—Signaling Pathways—APC—kidney cancer	6.94e-05	0.000251	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling by GPCR—ANXA1—kidney cancer	6.93e-05	0.00025	CbGpPWpGaD
Orlistat—PLA2G4A—Integrated Pancreatic Cancer Pathway—KRAS—kidney cancer	6.89e-05	0.000249	CbGpPWpGaD
Orlistat—CYP3A4—Biological oxidations—PTGS1—kidney cancer	6.84e-05	0.000247	CbGpPWpGaD
Orlistat—PLA2G4A—Platelet activation, signaling and aggregation—MAPK3—kidney cancer	6.82e-05	0.000246	CbGpPWpGaD
Orlistat—PNLIP—Disease—CTNNB1—kidney cancer	6.74e-05	0.000243	CbGpPWpGaD
Orlistat—DAGLB—Signaling by GPCR—PIK3CA—kidney cancer	6.63e-05	0.000239	CbGpPWpGaD
Orlistat—DAGLA—Signaling by GPCR—PIK3CA—kidney cancer	6.63e-05	0.000239	CbGpPWpGaD
Orlistat—PNLIP—Signaling Pathways—POMC—kidney cancer	6.61e-05	0.000239	CbGpPWpGaD
Orlistat—FASN—Disease—BRAF—kidney cancer	6.59e-05	0.000238	CbGpPWpGaD
Orlistat—DAGLA—Signaling Pathways—RAF1—kidney cancer	6.58e-05	0.000237	CbGpPWpGaD
Orlistat—DAGLB—Signaling Pathways—RAF1—kidney cancer	6.58e-05	0.000237	CbGpPWpGaD
Orlistat—PNLIP—Disease—PTEN—kidney cancer	6.56e-05	0.000237	CbGpPWpGaD
Orlistat—DAGLB—Signaling Pathways—RELA—kidney cancer	6.55e-05	0.000236	CbGpPWpGaD
Orlistat—DAGLA—Signaling Pathways—RELA—kidney cancer	6.55e-05	0.000236	CbGpPWpGaD
Orlistat—PNLIP—Signaling Pathways—BRAF—kidney cancer	6.53e-05	0.000236	CbGpPWpGaD
Orlistat—DAGLB—Signaling Pathways—ERBB2—kidney cancer	6.51e-05	0.000235	CbGpPWpGaD
Orlistat—DAGLA—Signaling Pathways—ERBB2—kidney cancer	6.51e-05	0.000235	CbGpPWpGaD
Orlistat—PLA2G4A—Platelet activation, signaling and aggregation—MAPK1—kidney cancer	6.49e-05	0.000234	CbGpPWpGaD
Orlistat—DAGLB—Signaling Pathways—MTOR—kidney cancer	6.42e-05	0.000232	CbGpPWpGaD
Orlistat—DAGLA—Signaling Pathways—MTOR—kidney cancer	6.42e-05	0.000232	CbGpPWpGaD
Orlistat—PLA2G4A—Integrated Pancreatic Cancer Pathway—PIK3CA—kidney cancer	6.33e-05	0.000229	CbGpPWpGaD
Orlistat—PNLIP—Metabolism—PTGS2—kidney cancer	6.3e-05	0.000228	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism—CRABP1—kidney cancer	6.29e-05	0.000227	CbGpPWpGaD
Orlistat—CYP3A4—Phase 1 - Functionalization of compounds—POMC—kidney cancer	6.19e-05	0.000223	CbGpPWpGaD
Orlistat—FASN—Metabolism of lipids and lipoproteins—PIK3CA—kidney cancer	6.16e-05	0.000223	CbGpPWpGaD
Orlistat—PLA2G4A—Integrated Pancreatic Cancer Pathway—TP53—kidney cancer	6.13e-05	0.000221	CbGpPWpGaD
Orlistat—DAGLB—Signaling Pathways—CDKN1B—kidney cancer	6.03e-05	0.000218	CbGpPWpGaD
Orlistat—DAGLA—Signaling Pathways—CDKN1B—kidney cancer	6.03e-05	0.000218	CbGpPWpGaD
Orlistat—DAGLB—Signaling Pathways—IL2—kidney cancer	5.9e-05	0.000213	CbGpPWpGaD
Orlistat—DAGLA—Signaling Pathways—IL2—kidney cancer	5.9e-05	0.000213	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism—ITPR2—kidney cancer	5.85e-05	0.000211	CbGpPWpGaD
Orlistat—DAGLA—Signaling Pathways—CCND1—kidney cancer	5.75e-05	0.000208	CbGpPWpGaD
Orlistat—DAGLB—Signaling Pathways—CCND1—kidney cancer	5.75e-05	0.000208	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—AKAP13—kidney cancer	5.75e-05	0.000208	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—CASP2—kidney cancer	5.75e-05	0.000208	CbGpPWpGaD
Orlistat—DAGLB—Signaling Pathways—JUN—kidney cancer	5.74e-05	0.000207	CbGpPWpGaD
Orlistat—DAGLA—Signaling Pathways—JUN—kidney cancer	5.74e-05	0.000207	CbGpPWpGaD
Orlistat—DAGLB—Signaling Pathways—CTNNB1—kidney cancer	5.69e-05	0.000206	CbGpPWpGaD
Orlistat—DAGLA—Signaling Pathways—CTNNB1—kidney cancer	5.69e-05	0.000206	CbGpPWpGaD
Orlistat—PLA2G4A—Platelet activation, signaling and aggregation—PIK3CA—kidney cancer	5.63e-05	0.000203	CbGpPWpGaD
Orlistat—PNLIP—Disease—MAPK3—kidney cancer	5.61e-05	0.000203	CbGpPWpGaD
Orlistat—FASN—Metabolism—POMC—kidney cancer	5.59e-05	0.000202	CbGpPWpGaD
Orlistat—DAGLA—Signaling Pathways—PTEN—kidney cancer	5.55e-05	0.0002	CbGpPWpGaD
Orlistat—DAGLB—Signaling Pathways—PTEN—kidney cancer	5.55e-05	0.0002	CbGpPWpGaD
Orlistat—FASN—Disease—RAF1—kidney cancer	5.51e-05	0.000199	CbGpPWpGaD
Orlistat—PNLIP—Metabolism—PTEN—kidney cancer	5.5e-05	0.000199	CbGpPWpGaD
Orlistat—PNLIP—Disease—MYC—kidney cancer	5.46e-05	0.000197	CbGpPWpGaD
Orlistat—PNLIP—Signaling Pathways—RAF1—kidney cancer	5.45e-05	0.000197	CbGpPWpGaD
Orlistat—FASN—Disease—ERBB2—kidney cancer	5.45e-05	0.000197	CbGpPWpGaD
Orlistat—PNLIP—Signaling Pathways—RELA—kidney cancer	5.43e-05	0.000196	CbGpPWpGaD
Orlistat—PNLIP—Signaling Pathways—ERBB2—kidney cancer	5.39e-05	0.000195	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism of lipids and lipoproteins—POMC—kidney cancer	5.39e-05	0.000195	CbGpPWpGaD
Orlistat—FASN—Disease—MTOR—kidney cancer	5.38e-05	0.000194	CbGpPWpGaD
Orlistat—FASN—Disease—CD4—kidney cancer	5.37e-05	0.000194	CbGpPWpGaD
Orlistat—PNLIP—Disease—MAPK1—kidney cancer	5.34e-05	0.000193	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism—ACHE—kidney cancer	5.33e-05	0.000192	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism—GSTT1—kidney cancer	5.33e-05	0.000192	CbGpPWpGaD
Orlistat—FASN—Disease—PTGS2—kidney cancer	5.33e-05	0.000192	CbGpPWpGaD
Orlistat—PNLIP—Signaling Pathways—MTOR—kidney cancer	5.32e-05	0.000192	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—GRB7—kidney cancer	5.26e-05	0.00019	CbGpPWpGaD
Orlistat—CYP3A4—Biological oxidations—GSTP1—kidney cancer	5.06e-05	0.000183	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism—SCARB1—kidney cancer	5.05e-05	0.000182	CbGpPWpGaD
Orlistat—FASN—Disease—CDKN1B—kidney cancer	5.04e-05	0.000182	CbGpPWpGaD
Orlistat—PNLIP—Disease—KRAS—kidney cancer	5.04e-05	0.000182	CbGpPWpGaD
Orlistat—DAGLB—Signaling Pathways—VEGFA—kidney cancer	5.01e-05	0.000181	CbGpPWpGaD
Orlistat—DAGLA—Signaling Pathways—VEGFA—kidney cancer	5.01e-05	0.000181	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism—PTGS1—kidney cancer	4.99e-05	0.00018	CbGpPWpGaD
Orlistat—PNLIP—Signaling Pathways—CDKN1B—kidney cancer	4.99e-05	0.00018	CbGpPWpGaD
Orlistat—CYP3A4—Metapathway biotransformation—GSTP1—kidney cancer	4.99e-05	0.00018	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism—PSMD7—kidney cancer	4.9e-05	0.000177	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—ITPR2—kidney cancer	4.89e-05	0.000176	CbGpPWpGaD
Orlistat—PNLIP—Signaling Pathways—IL2—kidney cancer	4.89e-05	0.000176	CbGpPWpGaD
Orlistat—PLA2G4A—Hemostasis—RAF1—kidney cancer	4.88e-05	0.000176	CbGpPWpGaD
Orlistat—FASN—Disease—CTNNB1—kidney cancer	4.77e-05	0.000172	CbGpPWpGaD
Orlistat—PNLIP—Signaling Pathways—CCND1—kidney cancer	4.76e-05	0.000172	CbGpPWpGaD
Orlistat—PNLIP—Signaling Pathways—JUN—kidney cancer	4.75e-05	0.000172	CbGpPWpGaD
Orlistat—DAGLB—Signaling Pathways—MAPK3—kidney cancer	4.74e-05	0.000171	CbGpPWpGaD
Orlistat—DAGLA—Signaling Pathways—MAPK3—kidney cancer	4.74e-05	0.000171	CbGpPWpGaD
Orlistat—PNLIP—Signaling Pathways—CTNNB1—kidney cancer	4.72e-05	0.00017	CbGpPWpGaD
Orlistat—CYP3A4—Biological oxidations—GSTM1—kidney cancer	4.65e-05	0.000168	CbGpPWpGaD
Orlistat—FASN—Disease—PTEN—kidney cancer	4.64e-05	0.000168	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism—BCHE—kidney cancer	4.64e-05	0.000168	CbGpPWpGaD
Orlistat—PNLIP—Disease—PIK3CA—kidney cancer	4.63e-05	0.000167	CbGpPWpGaD
Orlistat—DAGLB—Signaling Pathways—MYC—kidney cancer	4.61e-05	0.000166	CbGpPWpGaD
Orlistat—DAGLA—Signaling Pathways—MYC—kidney cancer	4.61e-05	0.000166	CbGpPWpGaD
Orlistat—PNLIP—Signaling Pathways—PTEN—kidney cancer	4.6e-05	0.000166	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism—SLC5A5—kidney cancer	4.59e-05	0.000166	CbGpPWpGaD
Orlistat—CYP3A4—Metapathway biotransformation—GSTM1—kidney cancer	4.59e-05	0.000166	CbGpPWpGaD
Orlistat—DAGLB—Signaling Pathways—MAPK1—kidney cancer	4.51e-05	0.000163	CbGpPWpGaD
Orlistat—DAGLA—Signaling Pathways—MAPK1—kidney cancer	4.51e-05	0.000163	CbGpPWpGaD
Orlistat—FASN—Metabolism—PTGS2—kidney cancer	4.46e-05	0.000161	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—CTNNA1—kidney cancer	4.43e-05	0.00016	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism—SLC2A1—kidney cancer	4.43e-05	0.00016	CbGpPWpGaD
Orlistat—CYP3A4—Biological oxidations—CYP1A1—kidney cancer	4.41e-05	0.000159	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—EIF4EBP1—kidney cancer	4.41e-05	0.000159	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—HSPB1—kidney cancer	4.41e-05	0.000159	CbGpPWpGaD
Orlistat—PLA2G4A—Hemostasis—IL2—kidney cancer	4.38e-05	0.000158	CbGpPWpGaD
Orlistat—CYP3A4—Metapathway biotransformation—CYP1A1—kidney cancer	4.35e-05	0.000157	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism of lipids and lipoproteins—PTGS2—kidney cancer	4.3e-05	0.000155	CbGpPWpGaD
Orlistat—DAGLB—Signaling Pathways—KRAS—kidney cancer	4.26e-05	0.000154	CbGpPWpGaD
Orlistat—DAGLA—Signaling Pathways—KRAS—kidney cancer	4.26e-05	0.000154	CbGpPWpGaD
Orlistat—PNLIP—Signaling Pathways—VEGFA—kidney cancer	4.15e-05	0.00015	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—PSMD7—kidney cancer	4.1e-05	0.000148	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—TSC1—kidney cancer	4.1e-05	0.000148	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—ANXA1—kidney cancer	4.1e-05	0.000148	CbGpPWpGaD
Orlistat—FASN—Disease—MAPK3—kidney cancer	3.97e-05	0.000143	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—FLT1—kidney cancer	3.97e-05	0.000143	CbGpPWpGaD
Orlistat—PNLIP—Signaling Pathways—MAPK3—kidney cancer	3.93e-05	0.000142	CbGpPWpGaD
Orlistat—DAGLA—Signaling Pathways—PIK3CA—kidney cancer	3.91e-05	0.000141	CbGpPWpGaD
Orlistat—DAGLB—Signaling Pathways—PIK3CA—kidney cancer	3.91e-05	0.000141	CbGpPWpGaD
Orlistat—FASN—Metabolism—PTEN—kidney cancer	3.89e-05	0.00014	CbGpPWpGaD
Orlistat—PNLIP—Metabolism—PIK3CA—kidney cancer	3.88e-05	0.00014	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—ACY1—kidney cancer	3.88e-05	0.00014	CbGpPWpGaD
Orlistat—FASN—Disease—MYC—kidney cancer	3.86e-05	0.000139	CbGpPWpGaD
Orlistat—PNLIP—Signaling Pathways—MYC—kidney cancer	3.82e-05	0.000138	CbGpPWpGaD
Orlistat—DAGLB—Signaling Pathways—TP53—kidney cancer	3.79e-05	0.000137	CbGpPWpGaD
Orlistat—DAGLA—Signaling Pathways—TP53—kidney cancer	3.79e-05	0.000137	CbGpPWpGaD
Orlistat—FASN—Disease—MAPK1—kidney cancer	3.78e-05	0.000136	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism of lipids and lipoproteins—PTEN—kidney cancer	3.75e-05	0.000135	CbGpPWpGaD
Orlistat—PNLIP—Signaling Pathways—MAPK1—kidney cancer	3.74e-05	0.000135	CbGpPWpGaD
Orlistat—PLA2G4A—Hemostasis—VEGFA—kidney cancer	3.72e-05	0.000134	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism—GSTP1—kidney cancer	3.69e-05	0.000133	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—JUNB—kidney cancer	3.68e-05	0.000133	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—PAK1—kidney cancer	3.68e-05	0.000133	CbGpPWpGaD
Orlistat—FASN—Disease—KRAS—kidney cancer	3.57e-05	0.000129	CbGpPWpGaD
Orlistat—PNLIP—Signaling Pathways—KRAS—kidney cancer	3.53e-05	0.000127	CbGpPWpGaD
Orlistat—PLA2G4A—Hemostasis—MAPK3—kidney cancer	3.52e-05	0.000127	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism—ABCB1—kidney cancer	3.5e-05	0.000126	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling by GPCR—POMC—kidney cancer	3.4e-05	0.000123	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism—GSTM1—kidney cancer	3.4e-05	0.000123	CbGpPWpGaD
Orlistat—PLA2G4A—Hemostasis—MAPK1—kidney cancer	3.35e-05	0.000121	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—PDHB—kidney cancer	3.3e-05	0.000119	CbGpPWpGaD
Orlistat—CYP3A4—Biological oxidations—POMC—kidney cancer	3.29e-05	0.000119	CbGpPWpGaD
Orlistat—FASN—Disease—PIK3CA—kidney cancer	3.28e-05	0.000118	CbGpPWpGaD
Orlistat—PNLIP—Signaling Pathways—PIK3CA—kidney cancer	3.24e-05	0.000117	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism—CYP1A1—kidney cancer	3.22e-05	0.000116	CbGpPWpGaD
Orlistat—PLA2G4A—Hemostasis—KRAS—kidney cancer	3.16e-05	0.000114	CbGpPWpGaD
Orlistat—PNLIP—Signaling Pathways—TP53—kidney cancer	3.14e-05	0.000113	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—CCBL1—kidney cancer	3.1e-05	0.000112	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—IGF2—kidney cancer	3.01e-05	0.000109	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—CDKN2B—kidney cancer	2.99e-05	0.000108	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—IGF1R—kidney cancer	2.91e-05	0.000105	CbGpPWpGaD
Orlistat—PLA2G4A—Hemostasis—PIK3CA—kidney cancer	2.9e-05	0.000105	CbGpPWpGaD
Orlistat—PLA2G4A—Hemostasis—TP53—kidney cancer	2.81e-05	0.000101	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling by GPCR—RAF1—kidney cancer	2.8e-05	0.000101	CbGpPWpGaD
Orlistat—FASN—Metabolism—PIK3CA—kidney cancer	2.74e-05	9.91e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—GLIPR1—kidney cancer	2.69e-05	9.7e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—PPAT—kidney cancer	2.69e-05	9.7e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism of lipids and lipoproteins—PIK3CA—kidney cancer	2.64e-05	9.55e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling by GPCR—IL2—kidney cancer	2.51e-05	9.07e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—FH—kidney cancer	2.5e-05	9.02e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—APRT—kidney cancer	2.5e-05	9.02e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism—POMC—kidney cancer	2.4e-05	8.67e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—HIF1A—kidney cancer	2.39e-05	8.64e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—TSC2—kidney cancer	2.39e-05	8.62e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—GPC3—kidney cancer	2.35e-05	8.48e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—KDR—kidney cancer	2.29e-05	8.26e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—CA2—kidney cancer	2.28e-05	8.25e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—ALAD—kidney cancer	2.23e-05	8.04e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—ST3GAL2—kidney cancer	2.17e-05	7.85e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—ALDH1A1—kidney cancer	2.12e-05	7.67e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—KIT—kidney cancer	2.11e-05	7.61e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—APC—kidney cancer	2.11e-05	7.61e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—PGK1—kidney cancer	2.04e-05	7.35e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—SLC5A3—kidney cancer	2.04e-05	7.35e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling by GPCR—MAPK3—kidney cancer	2.02e-05	7.29e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—POMC—kidney cancer	2.01e-05	7.25e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—LDHB—kidney cancer	2e-05	7.21e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—BRAF—kidney cancer	1.98e-05	7.15e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling by GPCR—MAPK1—kidney cancer	1.92e-05	6.94e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism—PTGS2—kidney cancer	1.91e-05	6.91e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling by GPCR—KRAS—kidney cancer	1.81e-05	6.55e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—CA9—kidney cancer	1.73e-05	6.25e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism—PTEN—kidney cancer	1.67e-05	6.03e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling by GPCR—PIK3CA—kidney cancer	1.67e-05	6.02e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—RAF1—kidney cancer	1.65e-05	5.97e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—RELA—kidney cancer	1.65e-05	5.95e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—ERBB2—kidney cancer	1.64e-05	5.91e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—MTOR—kidney cancer	1.62e-05	5.83e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—CDKN1B—kidney cancer	1.52e-05	5.47e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—IL2—kidney cancer	1.48e-05	5.36e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—CRABP1—kidney cancer	1.47e-05	5.32e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—CCND1—kidney cancer	1.45e-05	5.22e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—JUN—kidney cancer	1.44e-05	5.21e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—CTNNB1—kidney cancer	1.43e-05	5.17e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—PTEN—kidney cancer	1.4e-05	5.04e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—ITPR2—kidney cancer	1.37e-05	4.94e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—VEGFA—kidney cancer	1.26e-05	4.55e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—ACHE—kidney cancer	1.25e-05	4.51e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—GSTT1—kidney cancer	1.25e-05	4.51e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—MAPK3—kidney cancer	1.19e-05	4.31e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—SCARB1—kidney cancer	1.18e-05	4.27e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism—PIK3CA—kidney cancer	1.18e-05	4.25e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—PTGS1—kidney cancer	1.17e-05	4.22e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—MYC—kidney cancer	1.16e-05	4.19e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—PSMD7—kidney cancer	1.15e-05	4.14e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—MAPK1—kidney cancer	1.13e-05	4.1e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—BCHE—kidney cancer	1.09e-05	3.93e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—SLC5A5—kidney cancer	1.07e-05	3.88e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—KRAS—kidney cancer	1.07e-05	3.87e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—SLC2A1—kidney cancer	1.04e-05	3.75e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—PIK3CA—kidney cancer	9.85e-06	3.56e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—TP53—kidney cancer	9.53e-06	3.44e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—GSTP1—kidney cancer	8.65e-06	3.12e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—ABCB1—kidney cancer	8.19e-06	2.96e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—GSTM1—kidney cancer	7.95e-06	2.87e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—CYP1A1—kidney cancer	7.54e-06	2.72e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—POMC—kidney cancer	5.62e-06	2.03e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—PTGS2—kidney cancer	4.48e-06	1.62e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—PTEN—kidney cancer	3.91e-06	1.41e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—PIK3CA—kidney cancer	2.76e-06	9.96e-06	CbGpPWpGaD
